orbofiban has been researched along with arginyl-glycyl-aspartic acid in 1 studies
Studies (orbofiban) | Trials (orbofiban) | Recent Studies (post-2010) (orbofiban) | Studies (arginyl-glycyl-aspartic acid) | Trials (arginyl-glycyl-aspartic acid) | Recent Studies (post-2010) (arginyl-glycyl-aspartic acid) |
---|---|---|---|---|---|
48 | 17 | 0 | 4,556 | 17 | 1,799 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adderley, SR; Fitzgerald, DJ | 1 |
1 other study(ies) available for orbofiban and arginyl-glycyl-aspartic acid
Article | Year |
---|---|
Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation.
Topics: Alanine; Animals; Apoptosis; Benzamidines; Caspase 3; Caspases; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium; Enzyme Activation; Enzyme Precursors; Eptifibatide; Humans; Kinetics; Ligands; Mice; Myocardium; Oligopeptides; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rats; Rats, Wistar; Time Factors; Umbilical Veins | 2000 |